Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Blincyto Blinatumomab Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete
Blincyto blinatumomab B-cell precursor acute lymphoblastic leukemia, adults Received
Blincyto blinatumomab B-cell precursor acute lymphoblastic leukemia, pediatrics Received
Blincyto (Resubmission) Blinatumomab Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete
Bosulif Bosutinib Chronic Myeloid Leukemia Reimburse with clinical criteria and/or conditions Complete
Bosulif (RFA) Bosutinib Chronic Myeloid Leukemia N/A Complete
Botox onabotulinumtoxinA Migraine, chronic Reimburse with clinical criteria and/or conditions Complete
Botox OnabotulinumtoxinA Urinary incontinence List with criteria/condition Complete
Botox OnabotulinumtoxinA Neurogenic detrusor overactivity List with clinical criteria and/or conditions Complete
Botox OnabotulinumtoxinA Migraine Do not list Complete